In late June, the American Association of Clinical Endocrinologists announced plans for a conference where U.S. and international experts will examine whether SGLT2 inhibitor side effects include diabetic ketoacidosis. Organizers hope the meeting will provide answers to questions from AACE members regarding recent reports and... Read More

Health Canada has announced that it will begin a safety review of (canagliflozin) Invokana and (dapagliflozin) Forxiga, medications which are part of a new class of drugs known as SGLT2 inhibitors that are approved to treat type 2 diabetes. The review will investigate possible Invokana... Read More

The FDA recently issued a safety communication about Invokana side effects that have led to hospital visits for a number of users. On the heels of that warning, Invokana manufacturer Janssen Pharmaceuticals published a press release touting the benefits of their type 2 diabetes drug, with... Read More